Probity Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.46M | Sell |
2,675
-98
| -4% | -$99.4K | 0.39% | 50 |
|
|
2025
Q4 | $2.98M | Sell |
2,773
-383
| -12% | -$366K | 0.48% | 41 |
|
|
2025
Q3 | $2.41M | Sell |
3,156
-71
| -2% | -$52.8K | 0.39% | 53 |
|
|
2025
Q2 | $2.52M | Sell |
3,227
-51
| -2% | -$39.6K | 0.44% | 45 |
|
|
2025
Q1 | $2.71M | Sell |
3,278
-167
| -5% | -$139K | 0.52% | 43 |
|
|
2024
Q4 | $2.66M | Sell |
3,445
-213
| -6% | -$176K | 0.51% | 41 |
|
|
2024
Q3 | $3.24M | Sell |
3,658
-335
| -8% | -$301K | 0.62% | 32 |
|
|
2024
Q2 | $3.62M | Sell |
3,993
-403
| -9% | -$322K | 0.75% | 28 |
|
|
2024
Q1 | $3.42M | Sell |
4,396
-375
| -8% | -$267K | 0.71% | 31 |
|
|
2023
Q4 | $2.78M | Sell |
4,771
-330
| -6% | -$193K | 0.61% | 28 |
|
|
2023
Q3 | $2.74M | Sell |
5,101
-149
| -3% | -$76.8K | 0.63% | 30 |
|
|
2023
Q2 | $2.46M | Buy |
+5,250
| New | +$2.2M | 0.54% | 33 |
|
|
2022
Q4 | $2.07M | Sell |
5,671
-713
| -11% | -$253K | 0.47% | 36 |
|
|
2022
Q3 | $2.06M | Sell |
6,384
-631
| -9% | -$200K | 0.51% | 33 |
|
|
2022
Q2 | $2.27M | Sell |
7,015
-212
| -3% | -$63.6K | 0.53% | 32 |
|
|
2022
Q1 | $2.07M | Sell |
7,227
-764
| -10% | -$197K | 0.43% | 41 |
|
|
2021
Q4 | $2.21M | Sell |
7,991
-533
| -6% | -$135K | 0.44% | 43 |
|
|
2021
Q3 | $1.97M | Sell |
8,524
-493
| -5% | -$122K | 0.41% | 49 |
|
|
2021
Q2 | $2.07M | Sell |
9,017
-827
| -8% | -$166K | 0.44% | 45 |
|
|
2021
Q1 | $1.84M | Buy |
+9,844
| New | +$1.93M | 0.41% | 51 |
|
|
2020
Q3 | $1.66M | Sell |
11,242
-629
| -5% | -$97.3K | 0.47% | 46 |
|
|
2020
Q2 | $1.95M | Sell |
11,871
-381
| -3% | -$58.5K | 0.6% | 35 |
|
|
2020
Q1 | $1.7M | Sell |
12,252
-428
| -3% | -$58.8K | 0.62% | 33 |
|
|
2019
Q4 | $1.67M | Sell |
12,680
-119
| -0.9% | -$13.8K | 0.5% | 44 |
|
|
2019
Q3 | $1.43M | Sell |
12,799
-90
| -0.7% | -$10K | 0.46% | 51 |
|
|
2019
Q2 | $1.43M | Sell |
12,889
-471
| -4% | -$55.5K | 0.47% | 49 |
|
|
2019
Q1 | $1.73M | Sell |
13,360
-155
| -1% | -$18.8K | 0.6% | 41 |
|
|
2018
Q4 | $1.56M | Sell |
13,515
-445
| -3% | -$49.7K | 0.58% | 43 |
|
|
2018
Q3 | $1.5M | Sell |
13,960
-253
| -2% | -$25.3K | 0.49% | 50 |
|
|
2018
Q2 | $1.21M | Buy |
14,213
+183
| +1% | +$15K | 0.43% | 55 |
|
|
2018
Q1 | $1.09M | Buy |
14,030
+471
| +3% | +$37.9K | 0.38% | 62 |
|
|
2017
Q4 | $1.15M | Buy |
13,559
+475
| +4% | +$40.4K | 0.4% | 50 |
|
|
2017
Q3 | $1.12M | Buy |
13,084
+182
| +1% | +$14.9K | 0.42% | 48 |
|
|
2017
Q2 | $1.06M | Sell |
12,902
-36
| -0.3% | -$2.94K | 0.4% | 50 |
|
|
2017
Q1 | $1.09M | Sell |
12,938
-167
| -1% | -$13.4K | 0.42% | 48 |
|
|
2016
Q4 | $964K | Buy |
13,105
+594
| +5% | +$44.2K | 0.41% | 53 |
|
|
2016
Q3 | $1M | Buy |
12,511
+830
| +7% | +$66.4K | 0.43% | 49 |
|
|
2016
Q2 | $920K | Buy |
+11,681
| New | +$879K | 0.41% | 53 |
|
Other funds holding LLY
VCM
VPM
Probity Advisors's LLY Position: Q1 2026 in Review
Probity Advisors reduced its Eli Lilly (LLY) stake by 3.5% in Q1 2026, selling an estimated $99.4K and leaving 2,675 shares worth $2.46M. The position accounts for 0.39% of the portfolio, ranked #50.
Probity Advisors first reported a position in LLY in Q2 2016 and has held it in 38 quarters since. The position peaked at $3.62M in Q2 2024. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Probity Advisors held 2,675 shares of Eli Lilly worth $2.46M as of Q1 2026.
- Probity Advisors sold 98 Eli Lilly shares in Q1 2026, an estimated $99.4K.
- Eli Lilly made up 0.39% of Probity Advisors's portfolio in Q1 2026, its #50 holding.
- Probity Advisors first reported a position in Eli Lilly in Q2 2016 and has held it in 38 quarters since.
- Probity Advisors's Eli Lilly position peaked at $3.62M in Q2 2024.
- 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Probity Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.